1. Date of download: 5/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Inhibition of Endogenous Interferon Beta by Neutralizing Antibodies Against Recombinant Interferon Beta Arch Neurol. 2010;67(9):1095-1101. doi:10.1001/archneurol.2010.218 Interferon bioactivity of different interferons (antigens) and their interferon beta concentrations. Luciferase activity against leukocyte interferon, diluted supernatant with fibroblast interferon, recombinant interferon beta-1a (Avonex; Biogen Idec, Cambridge, Massachusetts), and recombinant interferon beta-1b (Betaferon; Bayer Schering, Leverkusen, Germany) are shown with respective interferon beta concentrations, as measured using enzyme-linked immunosorbent assay. Figure Legend:

2. Date of download: 5/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Inhibition of Endogenous Interferon Beta by Neutralizing Antibodies Against Recombinant Interferon Beta Arch Neurol. 2010;67(9):1095-1101. doi:10.1001/archneurol.2010.218 Cross-reactivity of anti–interferon beta antibodies against different interferon antigens (see Figure 1 legend). Patients' serum samples (N = 150) are shown with different binding antibody (BAb) and neutralizing antibody (NAb) levels (x-axis) and their in vitro neutralizing capacities (y-axis). Statistically significant bioactivity levels between consecutive antibody categories are shown. Different BAb concentrations as measured by enzme-linked immunosorbent assay are denoted as negative (BAb−), low (BAb+), moderate (BAb++), and high (BAb+++) along with the parallel NAb status (ie, NAb-negative [NAb−] or NAb-positive [NAb+]). Figure Legend:

3. Date of download: 5/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Inhibition of Endogenous Interferon Beta by Neutralizing Antibodies Against Recombinant Interferon Beta Arch Neurol. 2010;67(9):1095-1101. doi:10.1001/archneurol.2010.218 Correlation of neutralizing capacity of serum samples against recombinant vs natural interferon beta. Significant positive correlations were observed between cross-reactivity of anti–interferon beta antibodies with fibroblast interferon and recombinant interferon beta- 1a (A) and interferon beta-1b (B). Spearman correlations and significance levels are shown. More scattered correlation points were observed between interferon beta-1b and fibroblast interferon in the low to moderate range of antibody levels. Figure Legend:

4. Date of download: 5/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Inhibition of Endogenous Interferon Beta by Neutralizing Antibodies Against Recombinant Interferon Beta Arch Neurol. 2010;67(9):1095-1101. doi:10.1001/archneurol.2010.218 Serum neutralizing capacity against different interferon antigens. We compared 10-fold-reduction units (TRU) per milliliter for fibroblast interferon (natural interferon beta; x-axis) and recombinant interferon beta-1a (Avonex; Biogen Idec, Cambridge, Massachusetts) and interferon beta-1b (Betaferon; Bayer Schering, Leverkusen, Germany) (y-axis). Five samples had a low binding antibody (BAb) serostatus, 14 were moderately BAb-positive, and 11 were highly BAb-positive. Comparable neutralizing antibody (NAb) titers were observed in assays that used interferon beta-1a and fibroblast interferon (Spearman r = 0.98), whereas the interferon beta-1b assay yielded lower titers. Closed and open squares denote Avonex-treated patients (n = 9); closed and open circles, Betaferon-treated patients (n = 12); and closed and open triangles, Rebif (Merck Serono, Geneva, Switzerland)–treated patients (n = 9). Solid symbols represent interferon beta-1a testing; open symbols, interferon beta-1b testing. Figure Legend: